Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$26.23 USD
+0.73 (2.86%)
Updated Apr 26, 2024 12:44 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 21 - 40 ( 716 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Stock Historically Cheap; Street Apathetic to Takeout Potential Down Here
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Near- Long-Term EXPAREL Growth Drivers Intact; Gross Margins Still a Focus
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
2Q23: Lowered Guide Clears Street''s Low Bar, Making Stock Easier to Own for 2H Upturn; PT to $63; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Near-Term Focus Remains on Improving Gross Margins Driving EXPAREL Growth; Q2
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Low Street 2Q Expectations; We Dont Expect Lowered Guide; Potential Near-Term CMS Upside; PT to $68; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1:23 Revenues Lay the Foundation for 2023; EXPAREL Growth Opportunities Ahead
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A